Mujib Ullah

Title: Molecular imaging and CD9 based nano-sensors promises to deliver a more precise diagnosis in clincial applicatons

Abstract:

Molecular imaging is a field of medical imaging that allows visualization, characterization, and measurement of biological processes at the molecular and cellular levels. It provides a non-invasive way to study the biological processes and functions in living organisms in real-time. There are several types of molecular imaging techniques, including positron emission tomography (PET), single photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), computed tomography (CT), and optical imaging. These techniques utilize various imaging agents or probes that are designed to target specific molecules or cellular processes in the body. Molecular imaging has a wide range of applications in medical research and clinical practice. It can be used for early detection, diagnosis, and monitoring of various diseases, including cancer, cardiovascular diseases, neurological disorders, and infectious diseases. It can also be used for drug development and evaluation, as well as for understanding the underlying mechanisms of disease and therapy. The level of CD9 expression can provide useful information for diagnostic and prognostic purposes, as well as for monitoring the response to therapy. CD9 is a gene that codes for a protein known as tetraspanin-29 (TSPAN29), which is a member of the tetraspanin family of transmembrane proteins. The CD9 protein is involved in a variety of cellular processes, including cell adhesion, migration, and signaling. A CD9 sensor refers to a biosensor that is designed to detect the presence or activity of CD9 molecules. Biosensors are analytical devices that use biological components, such as enzymes or antibodies, to detect and measure specific molecules in complex samples, such as blood, urine, or saliva. Overall, CD9 sensors for exosomes have the potential to provide valuable information for diagnosis, monitoring, and treatment of various diseases, including cancer. The development of CD9 sensors for exosomes could lead to the development of new diagnostic and therapeutic tools for precision medicine

Biography:

Dr. Mujib Ullah has completed his PhD in tissue engineering/regenerative medicine, and postdoctoral studies from Stanford University School of Medicine. Dr Ullah is the medical investigator in the Department of Regenerative Medicine, Stanford University. Previously he worked in Harvard University and MIT. He is editor-in-chief for Artificial Intelligence in Cancer, guest editor for ACS Nano, and section editor for Stem Cells Research and Therapy and Nature. He has published numerous papers and has served as an editorial board member for many journals, such as the American Journal of Bioscience and Bioengineering. Dr Ullah has designed many labs, protocols, and study sections. He has mentored many undergraduate, graduate, and postgraduate students. He has supervised and managed many projects and is the advisor for Bio Thinking and Bio Aims Society. He has received many grants, awards, and fellowship in the field of stem cells regeneration and the CPRIT award for Cancer therapies. He has established cell banks for worldwide distribution under NIH and FDA guidelines. He has developed quality assurance protocols for the Food and Drug Administration to monitor stem cell therapies in regenerative medicine.